Carboplatin dosing formulae: Gender bias and the use of creatinine-based methodologies

European Journal of Cancer

Volumn 38, Issue 1, 2002, Pages 11-16

  Calvert, A H ^a   Egorin, M J ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMIFOSTINE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; EDETATE CHROMIUM CR 51; FOLINIC ACID; IFOSFAMIDE; LOBRADIMIL; METHOTREXATE; PACLITAXEL;

ANALYTICAL ERROR; AREA UNDER THE CURVE; BLOOD SAMPLING; BLOOD TOXICITY; CLINICAL TRIAL; CREATININE CLEARANCE; DOSE CALCULATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSAGE FORM; DRUG EFFECT; DRUG ELIMINATION; DRUG MEGADOSE; EDITORIAL; GERM CELL TUMOR; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FUNCTION; LUNG NON SMALL CELL CANCER; MAXIMUM TOLERATED DOSE; METHODOLOGY; OVARY CANCER; PRIORITY JOURNAL; RELAPSE; SEX DIFFERENCE; THROMBOCYTOPENIA;

ANTINEOPLASTIC AGENTS; CARBOPLATIN; CREATININE; HUMANS; MAXIMUM TOLERATED DOSE; NEOPLASMS; SELECTION BIAS; SEX FACTORS;

EID: 0036137077     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(01)00340-9     Document Type: Editorial

References (52)

1. Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity
2. Early clinical studies with cis-diammine-1,1-cyclobutanedicarboxylate platinum II
3. Phase I clinical and pharmacologic trial of carboplatin daily for 5 days
4. Pharmacokinetics and dosage reduction of cis-diammine(1,1-cyclobutanedicarboxylato)platinum in patients with impaired renal function
5. The pharmacokinetics of cis-diammine-1,1-cyclobutane dicarboxylate platinum (II) (CBDCA) in patients with normal and impaired renal function
6. Prospective validation of a pharmacologically based dosing scheme for the cis-diamminedichloroplatinum(II) analogue diamminecyclobutane dicarboxylatoplatinum
7. Carboplatin dosage: Prospective evaluation of a simple formula based on renal function
8. Phase I studies with carboplatin at the Royal Marsden Hospital
9. Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian-cancer
10. Dose-effect study of carboplatin in ovarian cancer: A Danish ovarian cancer group study
11. Randomized trial of dose-intensity with single-agent carboplatin in patients with epithelial ovarian cancer
12. The optimization of carboplatin dose in carboplatin, etoposide and bleomycin combination chemotherapy for good prognosis metastatic nonseminomatous germ-cell tumors of the testis
13. Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ-cell tumors - A multiinstitutional study
14. Pharmacokinetics and pharmacodynamics of carboplatin administered in a high-dose combination regimen with thiotepa, cyclophosphamide and peripheral stem cell support
15. Calvert's formula and high-dose carboplatin [4]
16. Prospective validation of renal function-based carboplatin dosing in children with cancer: A United Kingdom children's cancer study group trial
17. Carboplatin pharmacokinetics in children: The development of a pediatric dosing formula
18. Impact of cyclophosphamide on relationships between carboplatin exposure and response or toxicity when used in the treatment of advanced ovarian cancer
19. A comparison of methods of calculation for estimating carboplatin AUC with a retrospective pharmacokinetic-pharmacodynamic analysis in patients with advanced non-small cell lung cancer
20. Effects of storage on the binding of carboplatin to plasma proteins
21. Sample handling for determination of free platinum in blood after cisplatin exposure
22. Phase I trial, including pharmacokinetic and pharmacodynamic correlations, of combination paclitaxel and carboplatin in patients with metastatic non-small-cell lung cancer
23. Glomerular filtration rate measurement in man by the single injection method using 51CrEDTA
24. Calvert's formula for dosing carboplatin: Overview and concerns of applicability in high-dose setting
25. Renal handling of carboplatin
26. Prediction of creatinine clearance from serum creatinine
27. Creatinine clearance: Bedside estimate
28. Phase I and pharmacologic study of the combination paclitaxel and carboplatin as first-line chemotherapy in stage III and IV ovarian cancer
29. Carboplatin in combination with paclitaxel in advanced ovarian cancer: Dose determination and pharmacokinetic and pharmacodynamic interactions
30. A clinical and pharmacokinetic study of the combination of carboplatin and paclitaxel for epithelial ovarian cancer
31. Pharmacokinetics of carboplatin administered in combination with the bradykinin agonist Cereport (RMP-7) for the treatment of brain tumours
32. Pharmacokinetics of carboplatin with and without amifostine in patients with solid tumors
33. Prediction of carboplatine clearance from morphological and biological patient characteristics
34. Evaluation of formulas using the serum creatinine level to calculate the optimal dosage of carboplatin
35. Prediction of carboplatin clearance calculated by patient characteristics or 24-hour creatinine clearance: A comparison of the performance of three formulae
36. A review of the pharmacokinetics and pharmacodynamics of combination carboplatin/paclitaxel
37. Adjustment of creatinine clearance improves accuracy of Calvert's formula for carboplatin dosing
38. Multi-institutional validation study of carboplatin dosing formula using adjusted serum creatinine level
39. Estimation of glomerular filtration rate in cancer patients
40. A limited sampling method for estimation of the carboplatin area under the curve
41. Validation of a limited sampling model for carboplatin in a high-dose chemotherapy combination
42. Population pharmacokinetics of carboplatin in children
43. A sequential Bayesian algorithm for dose individualisation of carboplatin
44. A Bayesian dosing method for carboplatin given by continuous infusion for 120 h
45. Limited-sampling models for estimation of the carboplatin area under the curve
46. A limited-sampling method for evaluation of the area under the curve of ultrafilterable carboplatin in children
47. Validation of techniques for the prediction of carboplatin exposure: Application of Bayesian methods
48. A limited sampling strategy for determining carboplatin AUC and monitoring drug dosage
49. Evaluation of two dose individualisation methods for carboplatin
50. A single-sample assay for the estimation of the area under the free carboplatin plasma concentration versus time curve
51. A limited-sampling model for the pharmacokinetics of carboplatin administered in combination with paclitaxel
52. Carboplatin and paclitaxel, alone and in combination: Dose escalation, measurement of renal function, and role of the p53 tumor suppressor gene